Development of metabolic syndrome components in adults with a healthy obese phenotype: A 3-year follow-up
Authors:
Abstract
There is a lack of data on the progression from a healthy obese phenotype toward an unhealthy obese phenotype and the development of metabolic syndrome (MetS). Our aim was to assess the development of MetS 3 years after screening in centrally obese individuals with a healthy obese phenotype and to evaluate the usefulness of repeated screening. Eighty-eight individuals (mean age 47 years, 88% female) with central obesity as their only MetS component (ATP III criteria) at baseline screening were re-evaluated for MetS status after 3 years. At follow-up, the cardiometabolic risk profile in centrally obese individuals with a healthy phenotype showed a tendency toward deterioration. Thirty-two percent developed at least one additional MetS component, 7% had developed MetS. Nobody had developed type 2 diabetes. An increased triglyceride level (n = 16) and an increased blood pressure (n = 18) were the components most often present at follow-up. The people developing additional MetS components had a lower education level compared with the group that preserved the healthy centrally obese phenotype (80 vs. 71% lower educated, P = 0.35). They also had slightly worse baseline levels of the risk factors. The number of centrally obese individuals developing an unhealthy phenotype in this relatively short follow-up period emphasizes the need for a regular surveillance of cardiometabolic parameters in centrally obese individuals. However, it is questionable whether a repeated screening for type 2 diabetes every 3 years, as recommended by the American Diabetes Association, in this category of patients is appropriate.Keywords
Funding Information
- Investigator Initiated Studies Program of Merck Sharp & Dome Corp
- Merck Sharp & Dome Corp
This publication has 35 references indexed in Scilit:
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Identifying people with metabolic syndrome in primary care by screening with a mailed tape measurePreventive Medicine, 2009
- Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam StudyCardiovascular Diabetology, 2008
- Metabolic Syndrome and Risk of Incident Cardiovascular Events and DeathJACC, 2007
- Metabolic Syndrome and Risk of Cardiovascular Disease: A Meta-AnalysisThe American Journal of Medicine, 2006
- The Metabolic Syndrome as Predictor of Type 2 DiabetesDiabetes Care, 2003
- Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndromeThe American Journal of Cardiology, 2003
- Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyThe Lancet, 2000
- Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialThe Lancet, 1999
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998